LOXO-305
E566975
LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
All labels observed (1)
| Label | Occurrences |
|---|---|
| LOXO-305 canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T6003725 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: LOXO-305 Context triple: [Loxo Oncology, developedDrug, LOXO-305]
-
A.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
B.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
C.
LOXO
LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: LOXO-305 Target entity description: LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
-
A.
LOXO-195
LOXO-195 is a next-generation, highly selective TRK inhibitor developed to treat cancers that have developed resistance to earlier TRK-targeted therapies.
-
B.
LOXO-292
LOXO-292, also known as selpercatinib, is a targeted cancer therapy that selectively inhibits RET kinase and is used to treat certain RET-altered thyroid and lung cancers.
-
C.
LOXO
LOXO was the stock ticker symbol for Loxo Oncology, a biopharmaceutical company focused on developing targeted cancer therapies before its acquisition.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Statements (42)
| Predicate | Object |
|---|---|
| instanceOf |
Bruton’s tyrosine kinase inhibitor
ⓘ
investigational drug ⓘ small molecule drug ⓘ targeted cancer therapy ⓘ |
| actsOnCellType | B lymphocytes ⓘ |
| belongsToPortfolioOf | Eli Lilly oncology pipeline ⓘ |
| bindingType | non-covalent ⓘ |
| clinicalDevelopmentPhase | clinical trials ⓘ |
| designedTo |
overcome resistance to covalent BTK inhibitors
ⓘ
retain activity in patients with BTK C481 mutations ⓘ |
| developedFor |
B-cell malignancies
ⓘ
Waldenström macroglobulinemia ⓘ chronic lymphocytic leukemia ⓘ mantle cell lymphoma ⓘ other relapsed or refractory B-cell non-Hodgkin lymphomas ⓘ small lymphocytic lymphoma ⓘ |
| developer |
Eli Lilly and Company
NERFINISHED
ⓘ
Loxo Oncology NERFINISHED ⓘ |
| dosingSchedule | once-daily ⓘ |
| drugClass |
BTK inhibitor
ⓘ
tyrosine kinase inhibitor ⓘ |
| generation | non-covalent next-generation BTK inhibitor ⓘ |
| hasAdministrationForm | oral tablet ⓘ |
| hasAlternativeName |
LOXO 305
NERFINISHED
ⓘ
Loxo-305 NERFINISHED ⓘ pirtobrutinib NERFINISHED ⓘ |
| hasEffect |
inhibition of B-cell receptor signaling
ⓘ
reduction of malignant B-cell proliferation ⓘ |
| hasMechanismOfAction | BTK inhibition ⓘ |
| hasProperty |
high kinome selectivity
ⓘ
reversible BTK binding ⓘ |
| hasTarget | Bruton’s tyrosine kinase NERFINISHED ⓘ |
| intendedUse |
treatment of chronic lymphocytic leukemia after prior BTK inhibitor therapy
ⓘ
treatment of relapsed or refractory B-cell malignancies ⓘ |
| investigatedIn |
other B-cell non-Hodgkin lymphomas
ⓘ
relapsed or refractory chronic lymphocytic leukemia ⓘ relapsed or refractory mantle cell lymphoma ⓘ |
| molecularTargetType | non-receptor tyrosine kinase ⓘ |
| routeOfAdministration | oral ⓘ |
| selectivity | highly selective for BTK ⓘ |
| therapeuticArea |
hematologic malignancies
ⓘ
oncology ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: LOXO-305 Description of subject: LOXO-305 is a highly selective, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor being developed as a targeted therapy for B-cell malignancies such as chronic lymphocytic leukemia.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology